INSMED Inc (INSM) stock
INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30100% above fair value
$121.16+3.09 (+2.62%)
Close on Nov 13, 2026Market cap $26.58BP/E –Yield –
Insmed operating margin
Operating margin is operating income as a percentage of revenue.
Insmed's operating margin for the twelve months ending Sep 30, 2026 was -37.1%. For fiscal 2025 it was -205.6%, against -241.5% the year before. The highest annual figure on record is -83.6% in fiscal 2009.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -205.6% | +35.9 |
| FY2024 | Dec 31, 2024 | -241.5% | −9.0 |
| FY2023 | Dec 31, 2023 | -232.5% | −46.1 |
| FY2022 | Dec 31, 2022 | -186.4% | +12.6 |
| FY2021 | Dec 31, 2021 | -199.0% | −37.7 |
| FY2020 | Dec 31, 2020 | -161.3% | +11.1 |
| FY2019 | Dec 31, 2019 | -172.4% | +2952.6 |
| FY2018 | Dec 31, 2018 | -3124.9% | −2646.6 |
| FY2013 | Dec 31, 2013 | -478.4% | +918.9 |
| FY2011 | Dec 31, 2011 | -1397.3% | −1280.4 |
| FY2010 | Dec 31, 2010 | -116.9% | −33.3 |
| FY2009 | Dec 31, 2009 | -83.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -17.0% | +240.1 |
| Q2 FY2026 | Jun 30, 2026 | -0.4% | +290.9 |
| Q1 FY2026 | Mar 31, 2026 | -50.1% | +217.2 |
| Q4 FY2025 | Dec 31, 2025 | -121.2% | +99.4 |
| Q3 FY2025 | Sep 30, 2025 | -257.1% | −28.7 |
| Q2 FY2025 | Jun 30, 2025 | -291.3% | +28.5 |
| Q1 FY2025 | Mar 31, 2025 | -267.3% | −74.6 |
| Q4 FY2024 | Dec 31, 2024 | -220.6% | −7.6 |
| Q3 FY2024 | Sep 30, 2024 | -228.4% | −41.7 |
| Q2 FY2024 | Jun 30, 2024 | -319.8% | −14.8 |
| Q1 FY2024 | Mar 31, 2024 | -192.7% | +34.5 |
| Q4 FY2023 | Dec 31, 2023 | -213.0% | +42.4 |
| Q3 FY2023 | Sep 30, 2023 | -186.8% | +1.8 |
| Q2 FY2023 | Jun 30, 2023 | -305.0% | −169.6 |
| Q1 FY2023 | Mar 31, 2023 | -227.2% | −58.0 |
| Q4 FY2022 | Dec 31, 2022 | -255.4% | −78.9 |
| Q3 FY2022 | Sep 30, 2022 | -188.5% | +33.1 |
| Q2 FY2022 | Jun 30, 2022 | -135.4% | +59.8 |
| Q1 FY2022 | Mar 31, 2022 | -169.2% | +39.3 |
| Q4 FY2021 | Dec 31, 2021 | -176.5% | +51.7 |
| Q3 FY2021 | Sep 30, 2021 | -221.6% | −92.8 |
| Q2 FY2021 | Jun 30, 2021 | -195.2% | −67.9 |
| Q1 FY2021 | Mar 31, 2021 | -208.5% | −44.7 |
| Q4 FY2020 | Dec 31, 2020 | -228.3% | −125.3 |
| Q3 FY2020 | Sep 30, 2020 | -128.8% | +16.4 |
| Q2 FY2020 | Jun 30, 2020 | -127.3% | +80.1 |
| Q1 FY2020 | Mar 31, 2020 | -163.7% | +153.6 |
| Q4 FY2019 | Dec 31, 2019 | -103.0% | +788.9 |
| Q3 FY2019 | Sep 30, 2019 | -145.3% | – |
| Q2 FY2019 | Jun 30, 2019 | -207.4% | – |
| Q1 FY2019 | Mar 31, 2019 | -317.4% | – |
| Q4 FY2018 | Dec 31, 2018 | -891.9% | – |
See a number that looks wrong?